In this interview we discuss the role of radiotherapy in treating women aged 65 and older with hormone-positive breast cancer with Dr. Ian Kunkler, professor of clinical oncology at the Edinburgh Cancer Research Center.
The addition of carboplatin chemotherapy or bevacizumab to the standard neoadjuvant chemotherapy boosted the number of women with triple-negative breast cancer who had no residual cancer at the time of surgery.
In a study presented at SABCS, breast cancer patients experiencing moderate joint pain from aromatase inhibitor-therapy had clinically meaningful improvements in pain and stiffness when they participated in an exercise program.
The addition of bevacizumab to the combination of chemotherapy and trastuzumab as adjuvant therapy did not influence invasive disease-free survival according to a new study result presented at SABCS.
Adding the drug dasatinib to standard antihormone therapy letrozole doubled the median progression-free survival of patients with hormone-receptor positive, HER2-negative breast cancer, according to the results of a small phase II study.
The aromatase inhibitor anastrozole reduced the risk for breast cancer by 53% among postmenopausal women at high-risk for the disease, according to trial results presented at SABCS.
A year-long exercise program reduced joint pain among breast cancer survivors taking aromatase inhibitors such as anastrozole, letrozole, and exemestane, according to the results of a study presented recently at the 2013 San Antonio Breas
Major studies looking at breast cancer screening with mammography may have more consistent findings than previously thought.
Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II
Major studies conducted to date looking at mammography screening and mortality have estimated that the number of women needed to be screened in order to prevent one breast cancer death ranged from 111 to 2,000, an almost 20-fold difference; however, the benefits of mammography may be more consistent than previously thought, according to a re-examination of these studies presented at the SABCS.